8.15
price down icon1.81%   -0.15
after-market Dopo l'orario di chiusura: 7.80 -0.35 -4.29%
loading

Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie

pulisher
05:00 AM

Amylyx Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Selection - PrintWeekIndia

05:00 AM
pulisher
01:58 AM

Is Amylyx Pharmaceuticals Inc. a good long term investmentConsistent high-yield stocks - PrintWeekIndia

01:58 AM
pulisher
09:48 AM

What analysts say about Amylyx Pharmaceuticals Inc. stockConsistently superior profits - PrintWeekIndia

09:48 AM
pulisher
Jul 23, 2025

Hypoglycemia Clinical, Companies, Therapeutic Assessment, - openPR.com

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Amylyx Pharmaceuticals Inc. stock priceHigh-return market picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Published on: 2025-07-22 15:57:30 - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

autocarpro> 2025> What drives Amylyx Pharmaceuticals Inc. stock priceRobust financial gains - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Amylyx Pharmaceuticals: High-Risk, High-Reward Biotech Play with Game-Changing Pipeline Catalysts in 2026 - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential (NASDAQ:AMLX) - Seeking Alpha

Jul 21, 2025
pulisher
Jul 16, 2025

Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Amylyx Pharmaceuticals Inc. stock price move sharplyVolume Spike Monitors - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jul 15, 2025
pulisher
Jul 14, 2025

AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 14, 2025
pulisher
Jul 14, 2025

TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga

Jul 14, 2025
pulisher
Jul 14, 2025

Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event By Investing.com - Investing.com South Africa

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx presents new exploratory analyses from avexitide trials for PBH - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Pharmaceuticals Reports Results of Phase 2b Post-Bariatric Hypoglycemia Clinical Trial - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial - NewsBreak: Local News & Alerts

Jul 14, 2025
pulisher
Jul 14, 2025

Transcript : Amylyx Pharmaceuticals, Inc.Special Call - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - BioSpace

Jul 14, 2025
pulisher
Jul 13, 2025

Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at The Goldman Sachs Group - MarketBeat

Jul 13, 2025
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):